MELE, GIUSEPPE
 Distribuzione geografica
Continente #
AS - Asia 569
NA - Nord America 336
EU - Europa 202
SA - Sud America 183
AF - Africa 22
OC - Oceania 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 1.315
Nazione #
US - Stati Uniti d'America 303
SG - Singapore 210
BR - Brasile 143
VN - Vietnam 109
CN - Cina 103
IT - Italia 88
HK - Hong Kong 39
BD - Bangladesh 29
FR - Francia 24
DE - Germania 22
FI - Finlandia 16
AR - Argentina 14
MX - Messico 14
KR - Corea 13
EC - Ecuador 12
IN - India 12
IQ - Iraq 10
GB - Regno Unito 9
RU - Federazione Russa 9
AT - Austria 8
PK - Pakistan 7
TR - Turchia 7
UA - Ucraina 7
ZA - Sudafrica 7
CA - Canada 6
ID - Indonesia 5
VE - Venezuela 5
PL - Polonia 4
SA - Arabia Saudita 4
UZ - Uzbekistan 4
AE - Emirati Arabi Uniti 3
CZ - Repubblica Ceca 3
DO - Repubblica Dominicana 3
ES - Italia 3
MA - Marocco 3
MY - Malesia 3
AU - Australia 2
CL - Cile 2
CO - Colombia 2
CR - Costa Rica 2
DZ - Algeria 2
EG - Egitto 2
ET - Etiopia 2
JP - Giappone 2
KE - Kenya 2
KG - Kirghizistan 2
NL - Olanda 2
PA - Panama 2
PE - Perù 2
PH - Filippine 2
TN - Tunisia 2
AO - Angola 1
AZ - Azerbaigian 1
BG - Bulgaria 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BS - Bahamas 1
CH - Svizzera 1
GT - Guatemala 1
HN - Honduras 1
HR - Croazia 1
IE - Irlanda 1
IL - Israele 1
JM - Giamaica 1
JO - Giordania 1
MD - Moldavia 1
NI - Nicaragua 1
PY - Paraguay 1
RO - Romania 1
SE - Svezia 1
SN - Senegal 1
TT - Trinidad e Tobago 1
TW - Taiwan 1
UY - Uruguay 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 1.315
Città #
Singapore 100
San Jose 47
Ho Chi Minh City 42
Florence 38
Hong Kong 37
Ashburn 34
Boardman 27
Beijing 25
Hefei 23
Dallas 22
Hanoi 21
Council Bluffs 18
Los Angeles 13
New York 13
Seoul 13
São Paulo 13
Lauterbourg 11
Munich 10
Shanghai 9
Helsinki 8
Milan 8
Santa Clara 8
Charlotte 7
Rio de Janeiro 7
Mexico City 6
Vienna 6
Chicago 5
Da Nang 5
Guayaquil 5
Haiphong 5
Lahore 5
Lappeenranta 5
Porto Alegre 5
Quito 5
Sesto Fiorentino 5
Washington 5
Aracaju 4
Baghdad 4
Buffalo 4
Curitiba 4
Naples 4
Noto 4
Orem 4
Rome 4
Tashkent 4
Atlanta 3
Bari 3
Biên Hòa 3
Campinas 3
Hillsboro 3
Johannesburg 3
Montreal 3
Paris 3
Raipur 3
Santo Domingo 3
Thái Nguyên 3
Turku 3
Warsaw 3
Addis Ababa 2
Belo Horizonte 2
Bishkek 2
Bologna 2
Brooklyn 2
Bắc Giang 2
Bắc Ninh 2
Carney 2
Caxias do Sul 2
Chennai 2
Denver 2
Enfield 2
Fortaleza 2
Frankfurt am Main 2
Hưng Yên 2
Iporá 2
Juiz de Fora 2
Kyiv 2
Lamezia Terme 2
Londrina 2
Nairobi 2
New Delhi 2
Ninh Bình 2
Nuremberg 2
Puchong 2
Recife 2
Ribeirão Preto 2
Riyadh 2
San José 2
San Luis 2
Secaucus 2
Sharjah 2
Sydney 2
Tokyo 2
Vancouver 2
Vĩnh Tường 2
Alvorada 1
Amman 1
Amsterdam 1
Angeles City 1
Ankara 1
Annaba 1
Totale 769
Nome #
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients 126
Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab-Refractory Multiple Myeloma Patients: A Multicenter Real-World Study 124
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials 123
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials 116
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective real-world experience with 200 cases outside of controlled clinical trials 110
Daratumumab-based regimens for patients with multiple myeloma plus extramedullary plasmacytomas or paraskeletal plasmacytomas: initial follow-up of an Italian multicenter observational clinical experience 108
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow-up of a multicenter, retrospective real-world experience with 321 cases outside of controlled clinical trials 103
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials 102
Prognostic Significance of +1q Alterations in Relapsed/Refractory Multiple Myeloma Treated With Daratumumab‐, Elotuzumab‐, and Carfilzomib‐Based Triplet Regimens: A Multicenter Real‐World Analysis of 635 Patients 87
Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID Study 84
Isatuximab, pomalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: the Italian, multicenter, retrospective clinical experience with 270 cases outside of controlled clinical trials 78
Lenalidomide maintenance after bortezomib, thalidomide and dexamethasone (VTD) induction and autologous stem cell transplantation: an Italian real-life study of 602 patients 71
REFINING HIGH-RISK MULTIPLE MYELOMA: ADVANCEMENTS IN GENOMIC, CLINICAL, AND PROGNOSTIC CRITERIA 70
Imaging in Plasma‐Cell Neoplasms: Italian Experts’ Recommendations 19
A nationwide Italian GIMEMA survey on tandem autologous stem cell transplantation for newly diagnosed multiple myeloma patients treated with daratumumab, bortezomib, thalidomide and dexamethasone 9
Totale 1.330
Categoria #
all - tutte 6.123
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.123


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/202311 0 0 0 0 0 0 7 0 0 0 4 0
2023/2024122 2 2 22 20 8 15 8 1 1 2 5 36
2024/2025283 2 18 5 10 16 16 10 22 39 36 34 75
2025/2026914 94 54 68 71 142 62 111 60 83 78 47 44
Totale 1.330